Literature DB >> 14734743

The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection.

Carole Guillonneau1, Cédric Louvet, Karine Renaudin, Jean-Marie Heslan, Michèle Heslan, Laurent Tesson, Caroline Vignes, Cécile Guillot, Yongwon Choi, Lawrence A Turka, Maria-Cristina Cuturi, Ignacio Anegon, Régis Josien.   

Abstract

We analyzed the role of TNF-related activation-induced cytokine (TRANCE), a member of the TNF family expressed on activated T cells that shares functional properties with CD40L, and its receptor-activating NF-kappaB (RANK) which is mostly expressed on mature dendritic cells, during allogenic responses in vivo using a rodent heart allograft model. TRANCE mRNA was strongly up-regulated in acutely rejected allografts on days 4 and 5 posttransplantation whereas RANK was detected as early as day 1 but did not show further up-regulation during the first week. Immunofluoresence analyses of heart allografts showed that 80 and 100% of TRANCE and RANK-expressing cells were T cells and APCs, respectively. We show for the first time that short-term TRANCE blockade using a mouse RANKIg fusion molecule can significantly prolong heart allograft survival in both rat and mouse models. Similarly, rat heart allografts transduced with a RANKIg encoding recombinant adenovirus exhibited a significant prolongation of survival (14.3 vs 7.6 days, p < 0.0001). However, TRANCE blockade using RANKIg did not appear to inhibit allogeneic T and B cell priming humoral responses against RANKIg. Interestingly, TRANCE blockade induced strong up-regulation of CD40 ligand (CD40L) mRNA in allografts. Combined CD40L and TRANCE blockade resulted in significantly decreased chronic allograft rejection lesions as well as allogeneic humoral responses compared with CD40L blockade alone. We conclude that TRANCE-RANK interactions play an important role during acute allograft rejection and that CD40L-independent allogeneic immune responses can be, at least in part, dependent on the TRANCE pathway of costimulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734743     DOI: 10.4049/jimmunol.172.3.1619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

2.  Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.

Authors:  Elodie Picarda; Séverine Bézie; Laetitia Boucault; Elodie Autrusseau; Stéphanie Kilens; Dimitri Meistermann; Bernard Martinet; Véronique Daguin; Audrey Donnart; Eric Charpentier; Laurent David; Ignacio Anegon; Carole Guillonneau
Journal:  JCI Insight       Date:  2017-02-09

3.  A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection.

Authors:  Mandy L Ford; Maylene E Wagener; Samantha S Hanna; Thomas C Pearson; Allan D Kirk; Christian P Larsen
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

4.  MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection.

Authors:  Elodie Picarda; Séverine Bézie; Vanessa Venturi; Klara Echasserieau; Emmanuel Mérieau; Aurélie Delhumeau; Karine Renaudin; Sophie Brouard; Karine Bernardeau; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

5.  IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

Authors:  Séverine Bézie; Elodie Picarda; Jason Ossart; Laurent Tesson; Claire Usal; Karine Renaudin; Ignacio Anegon; Carole Guillonneau
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

6.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.

Authors:  François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  Immunomodulation by blockade of the TRANCE co-stimulatory pathway in murine allogeneic islet transplantation.

Authors:  Anne Wojtusciszyn; Axel Andres; Philippe Morel; Solange Charvier; Mathieu Armanet; Christian Toso; Yongwon Choi; Domenico Bosco; Thierry Berney
Journal:  Transpl Int       Date:  2009-05-15       Impact factor: 3.782

8.  The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells.

Authors:  Li Zhou; Hongjie Wang; Xing Zhong; Yulan Jin; Qing-Sheng Mi; Ashok Sharma; Richard A McIndoe; Nikhil Garge; Robert Podolsky; Jin-Xiong She
Journal:  Genome Biol       Date:  2008-07-29       Impact factor: 13.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.